Ablative fractional laser-assisted treatments for keratinocyte carcinomas and its precursors-Clinical review and future perspectives.
Ablative fractional laser
Actinic keratoses
Bowen's disease
Combination therapy
Immunotherapy
Laser-assisted drug delivery
Non-melanoma skin cancer
Non-surgical treatment
Photodynamic therapy
Topical delivery
Journal
Advanced drug delivery reviews
ISSN: 1872-8294
Titre abrégé: Adv Drug Deliv Rev
Pays: Netherlands
ID NLM: 8710523
Informations de publication
Date de publication:
01 01 2020
01 01 2020
Historique:
received:
24
07
2019
revised:
26
11
2019
accepted:
05
01
2020
pubmed:
11
1
2020
medline:
9
9
2021
entrez:
11
1
2020
Statut:
ppublish
Résumé
Keratinocyte carcinomas (KC) are the most common malignant human neoplasms. Although surgery and destructive approaches are first-line treatments, topical therapies are commonly used. Due to limited uptake of topical agents across the skin barrier, clearance rates are often sub-optimal. In pre-clinical investigations, ablative fractional laser (AFL)-assisted drug delivery has demonstrated improved uptake of topical drugs commonly used to treat KC. In 22 clinical trials, the effect of AFL-assisted treatments has been investigated for actinic keratosis (AK; n = 14), Bowen's disease (BD; n = 5), squamous cell carcinoma (n = 1), and basal cell carcinoma (n = 7). The most substantial evidence currently exists for AFL-assisted photodynamic therapy for the treatment of AK and BD. AFL improved 12-months follow-up clearance rates of photodynamic therapy from 45.0-51.0% to 78.5-84.8% for AK and from 50.0-55.3% to 87.0-87.5% for BD. AFL-assisted pharmacological therapy is a promising tool for optimizing topical treatments of KC and its precursor lesions. Future developments include AFL-assisted immune activation, changing drug administration route of systemic therapies, and utilizing drug chemo-combinations.
Identifiants
pubmed: 31923431
pii: S0169-409X(20)30003-X
doi: 10.1016/j.addr.2020.01.001
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
185-194Informations de copyright
Copyright © 2020. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest AME has received a research grant from Leo iLab and equipment loan from PerfAction. UHO declares no conflicts of interest. MH has received research grants from Leo Pharma, Lutronic, Novoxel, Procter&Gamble and Sebacia, and received equipment or equipment loan from Cherry Imaging, Cynosure-Hologic, Lutronic, Novoxel and PerfAction. AMR has received research grants from Leo iLab, ASLMS, and the Skin Cancer Foundation, served as a consultant for Merz, Biofrontera, Dynamed, Canfield Scientific, Evolus, Quantia MD, Lam Therapeutics, Cutera, and Skinfix, sat on advisory board for Allergan Inc., received travel grants from Mavig and L'oreal, and received equipment loan from PerfAction.